Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Feb;38(2):184–188. doi: 10.1128/aac.38.2.184

Use of multivariate analysis to compare antimicrobial agents on the basis of in vitro activity data.

J M Hernández 1, P Conforti 1
PMCID: PMC284423  PMID: 8192440

Abstract

Multivariate techniques such as principal component analysis or similar factor analysis help in analyses of the simultaneous interrelationships among several variables. A comparative multivariate analysis on the in vitro activities of eight antimicrobial agents, including the novel molecule daptomycin, is presented. Multivariate analysis detects components or factors and establishes connections among antimicrobial agents on the basis of their different levels of participation in each factor. The first principal component was dominated by vancomycin, teicoplanin, and rifampin (0.94344, 0.92792, and 0.72127, respectively). The second principal component showed strong effects from imipenem, gentamicin, and cephalothin (0.87922, 0.86126, and 0.68870, respectively). Daptomycin stood out alone in the third principal component (0.83983). The first three components defined 81.5% of the total variance and could easily be represented graphically in a three-dimensional scatter plot. In this graphic representation, the eight antimicrobial agents clustered in three different spatial regions; daptomycin occupied a separate spatial position. The use of multivariate analysis offers a different approach to determination of the in vitro activities of new antimicrobial agents and adds some new data on the relationships among different classes. Notwithstanding its limitations, the application of these methods in microbiology and drug development could be an additional tool for use in processing information.

Full text

PDF
184

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alborn W. E., Jr, Allen N. E., Preston D. A. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Nov;35(11):2282–2287. doi: 10.1128/aac.35.11.2282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allen N. E., Alborn W. E., Jr, Hobbs J. N., Jr Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother. 1991 Dec;35(12):2639–2642. doi: 10.1128/aac.35.12.2639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Allen N. E., Hobbs J. N., Alborn W. E., Jr Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother. 1987 Jul;31(7):1093–1099. doi: 10.1128/aac.31.7.1093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Appelbaum P. C., Spangler S. K., Crotty E., Jacobs M. R. Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones. J Antimicrob Chemother. 1989 Apr;23(4):509–516. doi: 10.1093/jac/23.4.509. [DOI] [PubMed] [Google Scholar]
  5. Bingen E., Lambert-Zechovsky N., Leclercq R., Doit C., Mariani-Kurkdjian P. Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 1990 Nov;26(5):619–626. doi: 10.1093/jac/26.5.619. [DOI] [PubMed] [Google Scholar]
  6. Dealler S. F. In-vitro activity of LY146032 daptomycin and other agents against JK diphtheroids. J Antimicrob Chemother. 1988 Jun;21(6):807–808. doi: 10.1093/jac/21.6.807. [DOI] [PubMed] [Google Scholar]
  7. Debono M., Barnhart M., Carrell C. B., Hoffmann J. A., Occolowitz J. L., Abbott B. J., Fukuda D. S., Hamill R. L., Biemann K., Herlihy W. C. A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation. J Antibiot (Tokyo) 1987 Jun;40(6):761–777. doi: 10.7164/antibiotics.40.761. [DOI] [PubMed] [Google Scholar]
  8. Digranes A., Benonisen E. In vitro activity of daptomycin against 297 staphylococcal isolates. Chemotherapy. 1990;36(2):136–140. doi: 10.1159/000238759. [DOI] [PubMed] [Google Scholar]
  9. Ehlert F., Neu H. C. In vitro activity of LY146032 (daptomycin), a new peptolide. Eur J Clin Microbiol. 1987 Feb;6(1):84–90. doi: 10.1007/BF02097208. [DOI] [PubMed] [Google Scholar]
  10. Eliopoulos G. M., Willey S., Reiszner E., Spitzer P. G., Caputo G., Moellering R. C., Jr In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986 Oct;30(4):532–535. doi: 10.1128/aac.30.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fass R. J., Helsel V. L. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1986 Nov;30(5):781–784. doi: 10.1128/aac.30.5.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Greenwood D., Palfreyman J. Comparative activity of LY146032 against anaerobic cocci. Eur J Clin Microbiol. 1987 Dec;6(6):682–684. doi: 10.1007/BF02013071. [DOI] [PubMed] [Google Scholar]
  13. Hodinka R. L., Jack-Wait K., Wannamaker N., Walden T. P., Gilligan P. H. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial. Eur J Clin Microbiol. 1987 Feb;6(1):100–103. doi: 10.1007/BF02097211. [DOI] [PubMed] [Google Scholar]
  14. Hunter P. R., George R. C., Griffiths J. W. Mathematical modeling of antimicrobial susceptibility data of Staphylococcus haemolyticus for 11 antimicrobial agents, including three experimental glycopeptides and an experimental lipoglycopeptide. Antimicrob Agents Chemother. 1990 Sep;34(9):1769–1772. doi: 10.1128/aac.34.9.1769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jones R. N., Barry A. L. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother. 1987 Apr;31(4):625–629. doi: 10.1128/aac.31.4.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jorgensen J. H., Maher L. A., Redding J. S. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria. Eur J Clin Microbiol. 1987 Feb;6(1):91–96. doi: 10.1007/BF02097209. [DOI] [PubMed] [Google Scholar]
  17. Le Pennec M. P., Berardi-Grassias L. In-vitro activity of 13 antibiotics against clinical isolates of Streptococcus milleri. J Antimicrob Chemother. 1989 Oct;24(4):618–619. doi: 10.1093/jac/24.4.618. [DOI] [PubMed] [Google Scholar]
  18. Low D. E., McGeer A., Poon R. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations. Antimicrob Agents Chemother. 1989 Apr;33(4):585–588. doi: 10.1128/aac.33.4.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nord C. E., Lindmark A., Persson I. Susceptibility of Clostridium difficile to LY146032. Eur J Clin Microbiol. 1987 Apr;6(2):189–189. doi: 10.1007/BF02018207. [DOI] [PubMed] [Google Scholar]
  20. Swenson J. M., Facklam R. R., Thornsberry C. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob Agents Chemother. 1990 Apr;34(4):543–549. doi: 10.1128/aac.34.4.543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Weber D. J., Saviteer S. M., Rutala W. A., Thomann C. A. In vitro susceptibility of Bacillus spp. to selected antimicrobial agents. Antimicrob Agents Chemother. 1988 May;32(5):642–645. doi: 10.1128/aac.32.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. de la Maza L., Ruoff K. L., Ferraro M. J. In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother. 1989 Aug;33(8):1383–1384. doi: 10.1128/aac.33.8.1383. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES